CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

January 30, 2025 · Phase 3 readout

CAPR Phase 3 readout: a positive outcome, +6.5%

On January 30, 2025, CAP-1002 — Capricor Therapeutics, Inc. (Duchenne Muscular Dystrophy) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +6.5% in the window around the event.

The move

$14.27
1d before
$15.20
Event day
$15.04
1d after
$15.07
5d after

Pre-catalyst setup

+3.4%
30-day run-up
6316%
30-day volatility
0.4×
volume spike